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Glycolysis provides precursors for the synthesis of macromolecules and may contribute
to the ATP supply required for the constant and accelerated cellular duplication in
cancer cells. In consequence, inhibition of glycolysis has been reiteratively considered
as an anti-cancer therapeutic option. In previous studies, kinetic modeling of glycolysis
in cancer cells allowed the identification of the main steps that control the glycolytic
flux: glucose transporter, hexokinase (HK), hexose phosphate isomerase (HPI), and
glycogen degradation in human cervix HeLa cancer cells and rat AS-30D ascites
hepatocarcinoma. It was also previously experimentally determined that simultaneous
inhibition of the non-controlling enzymes lactate dehydrogenase (LDH), pyruvate kinase
(PYK), and enolase (ENO) brings about significant decrease in the glycolytic flux of cancer
cells and accumulation of intermediate metabolites, mainly fructose-1,6-bisphosphate
(Fru1,6BP), and dihydroxyacetone phosphate (DHAP), which are inhibitors of HK and
HPI, respectively. Here it was found by kinetic modeling that inhibition of cancer
glycolysis can be attained by blocking downstream non flux-controlling steps as
long as Fru1,6BP and DHAP, regulatory metabolites of flux-controlling enzymes, are
accumulated. Furthermore, experimental results and further modeling showed that
oxamate and iodoacetate inhibitions of PYK, ENO, and glyceraldehyde3-phosphate
dehydrogenase (GAPDH), but not of LDH and phosphoglycerate kinase, induced
accumulation of Fru1,6BP and DHAP in AS-30D hepatoma cells. Indeed, PYK, ENO, and
GAPDH exerted the highest control on the Fru1,6BP and DHAP concentrations. The high
levels of these metabolites inhibited HK and HPI and led to glycolytic flux inhibition, ATP
diminution, and accumulation of toxic methylglyoxal. Hence, the anticancer effects of
downstream glycolytic inhibitors are very likely mediated by this mechanism. In parallel, it
was also found that uncompetitive inhibition of the flux-controlling steps is a more potent
mechanism than competitive and mixed-type inhibition to efficiently perturb cancer
glycolysis.
Keywords: cancer glycolysis, metabolic regulation, uncompetitive inhibition, feed-back inhibition, enolase
inhibition, pyruvate kinase inhibition, oxamate
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INTRODUCTION
In recent years it has been extensively documented that oxidative
phosphorylation (OxPhos) is predominant for supplying ATP
in cancer cells under aerobic conditions (Zu and Guppy, 2004;
Moreno-Sánchez et al., 2007; Ralph et al., 2010). However,
cancer glycolysis becomes prevalent when OxPhos is down-
regulated by long-term hypoxia or high incidence of mutations
in mitochondrial DNA (Carew and Huang, 2002; Gatenby
and Gillies, 2004; Rodríguez-Enríquez et al., 2010; Hernández-
Reséndiz et al., 2015). Glycolysis also provides precursors for the
synthesis of the macromolecules required for the constant and
accelerated cellular duplication of cancer cells (Bauer et al., 2005).
In addition, the enhanced lactic acid (a glycolytic end-product)
production and secretion by cancer cells has been proposed
to promote evasion of the immune system and induction of
angiogenesis and metastasis (Lardner, 2001; Fischer et al., 2007).
In consequence, glycolysis inhibition has re-emerged as an
alternative therapeutic option for cancer (Warmoes and Locasale,
2014). In addition, cancer cells may induce oxidative stress on
neighboring stromal fibroblasts triggering mitophagy and hence
re-directing their energymetabolism toward glycolysis. In return,
the lactate produced and expelled by fibroblasts, as well as ketone
bodies, are now taken up and actively oxidized by cancer cells
to drive OxPhos, which presumably favors tumor growth. This
cell-cell interplay has been called reverseWarburg effect (Pavlides
et al., 2009; Martinez-Outschoorn et al., 2011).
By applying the fundamentals of metabolic control analysis
(Fell, 1997; Moreno-Sánchez et al., 2008, 2010), the enzymes
and transporters that control the glycolytic flux of cancer cells
have been identified. These are indeed the targets with the
highest therapeutic potential because their inhibition will have
greater negative effects on tumor glycolysis than inhibition of
low- or negligible flux-controlling steps. It was determined by
both, elasticity analysis and kinetic modeling (experimental
strategies of metabolic control analysis and bottom-up Systems
Biology, respectively), that the main controlling steps of cancer
glycolysis are the glucose transporter (GLUT), hexokinase (HK),
hexose phosphate isomerase (HPI), and glycogen degradation,
regardless the environmental conditions to which the cells were
exposed (normoxia/normoglycemia, hypoxia/hyperglycemia,
and normoxia/hypoglycemia; Marín-Hernández et al., 2006,
2011, 2014). Although the degree of flux control exerted by these
controlling steps slightly changes among the different conditions,
the main controlling steps remain the same, which emphasizes
the fact that cancer glycolysis is also tightly regulated despite its
flux enhancement.
However, non-flux-controlling glycolytic steps such as
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), pyruvate
kinase (PYK), and lactate dehydrogenase (LDH) have been also
proposed as suitable targets for inhibition of cancer glycolysis
Abbreviations: DHAP, dihydroxyacetone-phosphate; ENO, enolase; Ery4P,
erythrose-4-phosphate; Fru1,6BP, fructose-1,6-biphosphate; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; Glc6P, glucose 6-phosphate; GLUT,
glucose transporter; HK, hexokinase; HPI, hexosephosphate isomerase; LDH,
lactate dehydrogenase; 6PG, 6-phosphogluconate; PYK, pyruvate kinase; TPI,
triosephosphate isomerase.
(Ganapathy-Kanniappan et al., 2012; Ganapathy-Kanniappan
and Geschwind, 2013; Daniele et al., 2015). Inhibition of any
of these three non-controlling enzymes induces a moderate
decrease in the growth of cancer cells (Tang et al., 2012;
Daniele et al., 2015). However, this anticancer effect could
be rather linked to inhibition of the “moonlighthing” or
accessory functions of glycolytic enzymes which include roles in
cancer development and promotion and cell cycle progression
(Ganapathy-Kanniappan and Geschwind, 2013; Hu et al., 2014).
On the other hand, the glycolytic metabolites glucose-6-
phosphate (Glc6P) and fructose-1,6-bisphosphate (Fru1,6BP)
and the pentose phosphate pathway metabolites erythrose-4-
phosphate (Ery4P) and 6-phosphogluconate (6PG) can modulate
the activities of the controlling enzymes HK and HPI through
competitive and mixed-type inhibitions. Furthermore, some
metabolites that at low, physiological concentrations are
innocuous, at high concentrations may become inhibitors of the
controlling steps HK (Fru1,6BP) and HPI (dihydroxyacetone-
phosphate; DHAP), inducing significant inhibition of the
glycolytic flux in cancer cells (Moreno-Sánchez et al., 2016).
Elevated levels of Fru1,6BP and DHAP in cancer cells can be
achieved by inhibiting, simultaneously, down-stream enzymes
with negligible flux-control such as enolase (ENO), PYK, and
LDH. Therefore, inhibitors of these latter enzymes may also
function as anti-glycolytic drugs because they may indirectly
induce inhibition of the high flux-controlling HK and HPI.
To understand the mechanistic basis of why inhibition of
down-stream non-controlling glycolytic enzymes may affect the
pathway flux, it appears necessary to determine which are the
down-stream steps with high control on the concentrations of
the regulatory metabolites Fru1,6BP and DHAP (i.e., metabolite
concentration control coefficients).
Such a goal was pursued and resolved in the present paper
by using our published AS-30D and HeLa cells glycolysis
kinetic models (Marín-Hernández et al., 2011, 2014; Moreno-
Sánchez et al., 2016). Previous theoretical studies have suggested
that uncompetitive inhibition induces more severe toxic
effects on a metabolic pathway than competitive inhibition
(Cornish-Bowden, 1986; Eisenthal and Cornish-Bowden, 1998).
Therefore, in silico simulations of how different mechanisms
of inhibition (competitive, mixed-type, uncompetitive) on
controlling enzymes impact the pathway systemic properties
(fluxes and metabolite concentrations) were also carried out
using the kinetic glycolysis models.
It was concluded that (i) inhibition of GAPDH with
iodoacetate, or PYK/ENO with oxamate but not LDH, PGK,
or PGAM, induces Fru1,6BP and DHAP accumulation and
methylglyoxal production, leading to significant suppression
of glycolysis; and (ii) uncompetitive inhibition of the most
controlling pathway steps is the most direct and potent
mechanism to efficiently perturb cancer glycolysis.
MATERIALS AND METHODS
Chemicals
HK, Glc6PDH, HPI, aldolase, α-glycerophosphate
dehydrogenase, triosephosphate isomerase (TPI), LDH, and
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Fru6P were purchased from Roche (Mannheim, Germany).
Glucose, iodoacetate, methylglyoxal, NADH, NAD+, NADP+,
and oxamate were from Sigma Chemical (St Louis, MO, USA).
Isolation of Tumor Cells
AS-30D hepatocarcinoma cells were propagated in 200–250 g
weight female Wistar rats by intraperitoneal inoculation of 3mL
of ascitic liquid containing ∼4–6 × 108 cells/mL. After 5–6
days, the intraperitoneal cavity liquid was extracted and tumor
cells were isolated by centrifugation as previously described
(López-Gómez et al., 1993). Animal manipulation was carried
out in accordance with the recommendations of Mexican Official
Standard NOM-062-ZOO-1999. This study did not require
approval by the Ethics Committee of the Instituto Nacional de
Cardiología de México.
Glycolytic Fluxes and Metabolite
Concentrations
Hepatocarcinoma AS-30D cells (15mg cell protein/mL) were
incubated in saline Krebs-Ringer medium supplied with oxamate
(10 or 20mM) or iodoacetate (2 or 4mM) for 60min under
orbital shaking at 150 rpm and 37◦C; under such conditions cell
viability was always higher than 90%. Thereafter, a cell sample
was withdrawn (time 0) and 5mM glucose was added; after
further 10min of incubation another cell sample (time 10) was
withdrawn. The cell samples were immediately mixed with ice-
cold perchloric acid (final concentration of 3% v/v), vortexed
and centrifuged at 1800 × g for 1min at 4◦C. The supernatants
were neutralized with 3M KOH/0.1M Tris, further incubated in
ice for at least 30min and then centrifuged. The supernatants
were stored at −72◦C until use for determination of Glc6P,
Fru6P, Fru1,6BP, G3P, DHAP, ATP, ADP, and L-lactate contents
as described by Bergmeyer (1974). The rate of the glycolytic flux
was estimated from the difference in L-lactate contents from the
t = 0 and t = 10min samples. As glycogen degradation and
glutaminolysis are negligible in AS-30D cells (Marín-Hernández
et al., 2006), total L-lactate production did not require correction
provided by 2-DOG inhibition.
Methylglyoxal was determined by gas chromatography in a
ShimadzuGC2010 apparatus (Shimadzu; Kyoto, Japan) equipped
with a capillary column HP-PLOT/U of 30m length, 0.32mm
I.D. and 10µm film (Agilent, USA), and flame ionization
detector. A methylglyoxal standard curve was carried out in the
range of 0.3–30 nmoles, and the time of retention was 4.7min.
The equipment conditions were FID temperature 200◦C, column
temperature 180◦C, oven temperature 180◦C, and linear velocity
26.4 cm/s. He (10ml/min) and H2 (40ml/min) mix was used
as carrier gas. The cell sample (15mg/ml) was withdrawn after
time 10 and centrifuged at 1800 × g for 2min. 0.5mL of the
supernatant was removed and the cell pellet was resuspended in
the remaining supernatant. The suspension was sonicated with a
Branson sonicator three times for 15 s at 60% of maximal output
with 1min rest, in an ice bath. The sonicate was centrifuged at
20 800 × g for 5min. The supernantant was filtered and 1–2µl
were injected in the gas chromatograph. The limit of detection of
methylglyoxal was lower than 0.3 nmoles. The concentration in
the stock solution of methlyglyoxal was enzymatically calibrated
by using human ALDH2 and saturating NAD+.
Kinetic Modeling
The previous kinetic models of glycolysis built for HeLa
and AS-30D cells (Marín-Hernández et al., 2014; Moreno-
Sánchez et al., 2016) using the metabolic simulator GEPASI
version 3.3 (Mendes, 1993) were modified for the HK, HPI,
TPI, and GAPDH rate equations as described below. The
other rate equations remained unaltered, however, they are
here fully described (Supplementary Table 1) because model
updates previously developed are scattered in several papers
(Marín-Hernández et al., 2011, 2014; Moreno-Sánchez et al.,
2016). The models and simulations were also run in COPASI
software (Hoops et al., 2006) with no significant differences to
those of GEPASI (SBML files are included in Supplementary
Presentation 1). The great majority of the kinetic parameter
values used in the models were determined under the same
experimental conditions (K+-based medium at pH 7.0 and 37◦C;
Marín-Hernández et al., 2006, 2011, 2014; Rodríguez-Enríquez
et al., 2009; Moreno-Sánchez et al., 2012, 2016).
In the AS-30D model, kinetics of GLUT was defined as a
monosubstrate reversible Michaelis-Menten equation [Haldane
equation (Equation 1)] as it was previously determined
(Rodríguez-Enríquez et al., 2009; Marín-Hernández et al., 2011):
v =
Vmf
([
Glcout
]
−
[Glcin]
Keq
)
KGlcout
(
1+ [
Glcin]
KGlcin
)
+ Glcout
(1)
in which Glcout and Glcin and KGlcout and KGlcin are the extra-
and intra-cellular glucose concentrations and the Km values,
respectively; Keq is the equilibrium constant; and Vmf is the
maximal velocity in the forward reaction.
In the HeLa model, the rate-equation for GLUT was
changed to a double mono-substrate reversible Michaelis-
Menten equation (Equation 2), representing the co-existence of
two isoforms (Marín-Hernández et al., 2014),
v = Vmf



 f 1
([
Glcout
]
−
[Glcin]
Keq
)
KGlcout1
(
1 + [
Glcin]
KGlcin1
)
+ Glcout


+

 f 2
([
Glcout
]
−
[Glcin]
Keq
)
KGlcout2
(
1 + [
Glcin]
KGlcin2
)
+ Glcout




(2)
in which KGlcout1 and KGlcout2 are the Km values for extracellular
glucose of each GLUT isoform; and KGlcin1 and KGlcin2 are
the Km values for intracellular glucose of each GLUT isoform.
f 1 and f 2 are the fractional isoform contents determined by
Western blot analysis and enzyme kinetics (Marín-Hernández
et al., 2014). This two-components equation was proposed in
the previous study because cells grown in low glucose express
significant contents of both isoforms, GLUT1 and GLUT3
(Marín-Hernández et al., 2014).
The HK rate equation (Equation 3) used for the present
updated AS-30D model was a random Bi-Bi system (Segel,
1975) with mixed type inhibition by Fru1,6BP based on previous
experimental kinetic analysis (Moreno-Sánchez et al., 2016):
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v =
Vmf
α1KaKb
(
[A] [B]− [P][Q]Keq
)
1 + [A]Ka +
[B]
Kb
+
[A][B]
α1KaKb +
[P]
Kp +
[Q]
Kq +
[P][Q]
KpKq +
[A][Q]
KaKq +
[P][B]
KpKb
+
[I]
Ki +
[A][I]
α2KaKi
+
[A][I][B]
α1KaKbα2Ki
(3)
where A = [Glcin], B = [ATP], P = [Glc6P] and Q = [ADP].
Ka, Kb, Kp, and Kq are the Km values for the corresponding
substrates and products. α1 and α2 values are the factors by
which Ka (Kmglc) changes when B (ATP) and I (Fru1,6BP) are
bound to the enzyme, respectively. Ki is the inhibition constant
for Fru1,6BP (KiFru1,6BP).
In the HeLa model, the HK rate equation (Equation 4) was a
double random-bisubstrate Michaelis-Menten to also represent
the coexistence of two enzyme isoforms as previously reported
(Marín-Hernández et al., 2014),
v = Vmf



 f 1Ka1Kb
(
[A] [B] − [P][Q]Keq
)
1 + [A]Ka1 +
[B]
Kb
+
[A][B]
Ka1Kb +
[P]
Kp +
[Q]
Kq +
[P][Q]
KpKq +
[A][Q]
Ka1Kq +
[P][B]
KpKb


+

 f 2Ka2Kb
(
[A] [B]− [P][Q]Keq
)
1 + [A]Ka2 +
[B]
Kb
+
[A][B]
Ka2Kb +
[P]
Kp +
[Q]
Kq +
[P][Q]
KpKq +
[A][Q]
Ka2Kq +
[P][B]
KpKb




(4)
in which Ka1 and Ka2 represent the Km values for Glcin of
each isoform; f 1 and f 2 are the fractional isoform contents
experimentally determined from the activities of HKI and HKII
in HeLa cellular extracts (Marín-Hernández et al., 2014).
The HPI rate equation in the HeLa model was considered
as a monoreactant reversible Michaelis-Menten equation
(Equation 5) with (a) competitive (Marín-Hernández et al.,
2011, 2014), (b) uncompetitive (Segel, 1975), and (c) mixed type
inhibition (Segel, 1975) by Ery4P, 6PG, and Fru1,6BP.
(a) v =
Vmf
[Glc6P]
Kglc6p
− Vmr
[Fru6P]
Kfru6p
1 + [Glc6P]Kglc6p +
[Fru6P]
Kfru6p
+
[ERY4P]
Kery4p
+
[Fru1,6BP]
Kfru1,6bp
+
[6PG]
K6pg
(b) v =
Vmf
Kglc6p
[
Glc6P
]
−
Vmr
Kfru6p
[Fru6P]
1+
(
[Glc6P]
Kglc6p
)
∗
(
1+ [ERY4P]Kery4p +
[Fru1,6BP]
Kfru1,6bp
+
[6PG]
K6pg
)
+
(
[Fru6P]
Kfru6p
)
∗
(
1+ [ERY4P]Kery4p +
[Fru1,6BP]
Kfru1,6bp
+
[6PG]
K6pg
)
(c) v =
Vmf [Glc6P]
Kglc6p
(
1 + [ERY4P]Kery4p
+
[Fru1,6BP]
Kfru1,6bp
+
[6PG]
K6pg
) − Vmr [Fru6P]
Kfru6p
(
1 + [ERY4P]Kery4p
+
[Fru1,6BP]
Kfru1,6bp
+
[6PG]
K6pg
)
1 +
(
[Glc6P]
Kglc6p
)
∗
(
1 + [ERY4P]
∝Kery4p
+
[Fru1,6BP]
∝Kfru1,6bp
+
[6PG]
∝K6pg
1 + [ERY4P]Kery4p
+
[Fru1,6BP]
Kfru1,6bp
+
[6PG]
K6pg
)
+
(
[Fru6P]
Kfru6p
)
∗
(
1 + [ERY4P]
∝Kery4p
+
[Fru1,6BP]
∝Kfru1,6bp
+
[6PG]
∝K6pg
1 + [ERY4P]Kery4p
+
[Fru1,6BP]
Kfru1,6bp
+
[6PG]
K6pg
)
(5)
The HPI rate equation in the AS-30D model was a monoreactant
reversible equation (Equation 6) with competitive inhibition
by four modulators: Ery4P, 6PG, Fru1,6BP and DHAP as
experimentally determined (Moreno-Sánchez et al., 2016):
v =
Vmf [
Glc6P]
Kglc6p
− Vmr [Fru6P]Kfru6P
1+ [
Glc6P]
Kglc6p
+
[Fru6P]
Kfru6p
+
[ERY4P]
Kery4p
+
[Fru1,6BP]
Kfru1,6bp
+
[PG]
K6pg
+
[DHAP]
Kdhap
(6)
The rate equation for PFK-I (Equation 7) in all kinetic models
was the concerted transition model of Monod, Wyman and
Changeux for exclusive ligand binding (Fru6P, activators, and
inhibitors) together with mixed-type activation and simple
Michaelis–Menten terms for ATP and reverse reaction (Marín-
Hernández et al., 2011, 2014) as established by experimental
kinetic analysis (Moreno-Sánchez et al., 2012). ATP and citrate
are the allosteric inhibitors. L is the allosteric transition
constant; KaFru26BP is the activation constant for Fru26BP;
KiCIT and KiATP are the inhibition constants for citrate and
ATP; α and β are the factors by which KFru6P and Vmax
change when a mixed-type activator is bound to the active
enzyme.
Probably derived from the high complexity of the PFK1
rate equation, the algorithms used by COPASI to generate the
ordinary differential equations to calculate the variation in the
metabolite concentrations assign the role of the first substrate (or
product) to that defined in the reaction specification window.
If the order of substrates and products in the reaction does not
match with that stated in the rate equation, then the computer
program mix-up the identity of the ligands in the ordinary
differential equations. Therefore, to correct for this type of errors
both the syntax reaction and the rate equation have to be
displayed in the same order of substrates and products; then one
should be aware that the reaction syntax does not necessarily
reflect the order of binding in the enzyme, which defines the type
of reaction mechanism.
Reaction: ATP+ Fru6P= ADP+ Fru1,6BP
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v = Vm


( [ATP]
KATP
1 + [ATP]KATP
)(
1 + βFru26BP
αKaFru26BP
1 + Fru26BP
αKaFru26BP
)


Fru6P
(
1 + Fru26BP
αKaFru26BP
)
KFru6P
(
1 + Fru26BPKaFru26BP
)
[
1 +
Fru6P
(
1 + Fru26BP
αKaFru26BP
)
KFru6P
(
1 + Fru26BPKaFru26BP
)
]3
L
(
1 + [CIT]KiCIT
)4(
1 + [ATP]KiATP
)4
(
1 + Fru26BPKaFru26BP
)4 +
[
1 +
Fru6P
(
1 + Fru26BP
αKaFru26BP
)
KFru6P
(
1 + Fru26BPKaFru26BP
)
]4


−

 [ADP][Fru16BP]KADPKFru16BPKeq
[ADP]
KADP
+
[Fru16BP]
KFru16BP
+
[ADP][Fru16BP]
KADPKFru16BP
+ 1




(7)
The ALDO rate equation was the reversible Uni-Bi random
Michaelis-Menten equation (Equation 8) in all kinetic models as
was reported in previous kinetic models (Marín-Hernández et al.,
2011, 2014).
v =
Vmf [Fru1,6BP]Kfru1,6bp
− Vmr [DHAP][G3P]KDHAPKG3P
1 + [Fru1,6BP]Kfru1,6bp +
[DHAP]
KDHAP
+
[G3P]
KG3P
+
[DHAP][G3P]
KDHAPKG3P
(8)
Kinetics for TPI in the AS-30D model was here depicted by
a mono-substrate simple reversible Michaelis-Menten equation
(Equation 9) with mixed type inhibition by Fru1,6BP as it was
previously determined (Moreno-Sánchez et al., 2016):
v =
Vmf [S]
Ks
(
1 + [I]Ki
) − Vmr [P]
Kp
(
1 + [I]Ki
)
1 + [S]
Ks
(
1 + [I]Ki
1 + [I]
∝Ki
) + [P]
Kp
(
1 + [I]Ki
1 + [I]
∝Ki
) (9)
α value is the factor by whichKs andKp change when Fru1,6BP is
bound to the enzyme; Ki is the inhibition constant for Fru1,6BP
(KiFru1,6BP).
In the HeLa model, the TPI rate equation (Equation 10) was
a mono-substrate simple reversible Michaelis-Menten equation
as it was previously determined (Marín-Hernández et al., 2011,
2014) with no inhibitors:
v =
Vmf [S]Ks − Vmr
[P]
Kp
1+ [S]Ks +
[P]
Kp
(10)
GAPDH kinetics in the AS-30D model was here described
by a simplified ordered Ter-Bi Michaelis-Menten equation
(Equation 11) with mixed type inhibition by Fru1,6BP as
previously determined (Moreno-Sánchez et al., 2016):
v =
Vmf [A][B][C]
KaKbKc
− Vmr [P][Q]KpKq
1 + [A]Ka +
[A][B]
KaKb
+
[A][B][C]
KaKbKc
+
[P][Q]
KpKq +
[Q]
Kq +
[I]
Ki +
[A][B][I]
KaKb∝Ki
+
[A][B][C][I]
KaKbKc∝Ki
+
[P][Q][I]
KpKq∝Ki
(11)
where A = [NAD+], B = [G3P], C = [Pi], P = [BPG], Q =
[NADH] with their respective affinity constants (Ka, Kb, Kc, Kp,
and Kq). Ki is the inhibition constant for Fru1,6BP (KiFru1,6BP). α
value is the factor by which Kb (KmG3P) changes when Fru1,6BP
is bound to the enzyme.
In the HeLa model, the GAPDH rate equation (Equation 12)
was a simplified ordered Ter-Bi Michaelis-Menten equation as
was previously determined and used in previous models (Marín-
Hernández et al., 2011, 2014).
v =
Vmf [A][B][C]
KaKbKc
− Vmr [P][Q]KpKq
1 + [A]Ka +
[A][B]
KaKb
+
[A][B][C]
KaKbKc
+
[P][Q]
KpKq +
[Q]
Kq
(12)
In all models the rate equations for PGAM and ENO were
depicted by mono-substrate simple reversible Michaelis-Menten
equation (Equation 13):
v =
Vmf [S]Ks − Vmr
[P]
Kp
1+ [S]Ks +
[P]
Kp
(13)
in which [S] and [P] are the respective concentrations of
substrates and products and their respective Km values (Ks and
Kp) which were experimentally determined in previous works
(Marín-Hernández et al., 2011, 2014).
The PYK rate equation (Equation 14) in all models was
defined as simple random-bisubstrate Michaelis-Menten that
represents the kinetics of the prevalent PYK isoform in cancer
cells with no cooperativity or allosteric modulation by typical
metabolites, as experimentally determined for AS-30D cells
(Marín-Hernández et al., 2014; Moreno-Sánchez et al., 2016). A,
B, P, and Q are PEP, ADP, Pyr, and ATP, respectively; Ka, Kb, Kp,
and Kq are the Km values for the corresponding substrates and
products.
v =
Vmf
KaKb
(
[A] [B]− [P][Q]Keq
)
1+ [A]Ka +
[B]
Kb
+
[A][B]
KaKb
+
[P]
Kp+
[Q]
Kq +
[P][Q]
KpKq +
[A][Q]
KaKq +
[P][B]
KpKb
(14)
In all models, the rate equations (Equation 15) for PGK and
LDH were defined by random Bi-Bi reversible Michaelis-Menten
for non-interacting substrates (α and β = 1) according to the
reported literature (Marín-Hernández et al., 2011, 2014; Moreno-
Sánchez et al., 2016);Ka,Kb,Kp, andKq are theKm values for the
corresponding substrates and products previously determined
(Marín-Hernández et al., 2011, 2014; Moreno-Sánchez et al.,
2016). In the case of PGK, A, B, P, and Q are 1,3BPG, ADP,
3PG, and ATP, respectively whereas for LDH they are NADH,
Pyr, Lactate and NAD+, respectively.
v =
Vmf [A][B]
αKaKb
− Vmr [P][Q]
βKpKq
1+ [A]Ka +
[B]
Kb
+
[A][B]
αKaKb
+
[P][Q]
βKpKq +
[P]
Kp +
[Q]
Kq
(15)
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In the HeLa model the rate-equation (Equation 16) for the
monocarboxylate transporter (MCT) activity was incorporated
(Marín-Hernández et al., 2014) since it catalyzes the expulsion
of lactate and H+. With the inclusion of this reaction, it can be
visualized why HeLa cell cultures become rapidly acidic. This
was a mono-substrate reversible Michaelis-Menten equation in
which Lacin and Lacout are the intra- and extra-cellular lactate
concentrations; KLacin and KLacout are the Km values for the intra
and extracellular lactate; Keq is the equilibrium constant of the
reaction. The equation only included lactate as a ligand because
kinetic parameters for the proton are not available.
v =
Vmf
(
[Lacin]−
[Lacout]
Keq
)
KLacin
(
1+ [Lacout]KLacout
)
+ Lacin
(16)
Molecular Docking Analysis
Crystal structures of human HK type I, TPI and GAPDH, and
mouse HPI, were obtained from the protein data bank (accession
numbers 4FOI, 1HTI and 3PFW, and 1U0F, respectively). The
three dimensional models of the ligands used in the study were
obtained from different crystal structures found in the protein
data bank or downloaded from PubChem (https://pubchem.ncbi.
nlm.nih.gov/). The models were optimized using the ArgusLab
4.0.1 (Planaria Software LLC, Seattle, WA) available at: http://
www.arguslab.com and Maestro, version 9.1 (Schrodinger, LLC,
New York, NY, 2010) softwares. For docking analysis, the
ligands from the above protein crystal structures were removed
using the software UCSF Chimera package 1.6 (Resource for
Biocomputing, Visualization, and Informatics at the University
of California, San Francisco, CA; supported by NIH P41
RR001081; Pettersen et al., 2004). The protein structure and
ligandmodels were prepared for docking using the software ADT
1.5.2 (Sanner, 1999; Morris et al., 2009). Docking analysis of
the enzyme structures and ligands were carried out using the
software Autodock 4.2.5.1 (Huey et al., 2007) available at http://
autodock.scripps.edu/. After docking, 100 conformations for
each ligand were obtained, and then clustered for analysis using
ADT 1.5.2 software. The conformations selected corresponded
to the lowest values of binding energy and Ki. Analysis of the
resulting structures and generation of the figures were achieved
with PyMOL (The PyMOL Molecular Graphics System, Version
1.2.r1, Schrodinger, LLC).
RESULTS
Effect of Metabolic Inhibition of Low
Flux–Controlling Enzymes in the Pathway
Flux
Inhibition of a low- or non-flux controlling step might be
regarded as a mishap or misleading option to decrease the
pathway flux because it requires almost complete inhibition (a
“pharmacological knock out” or >80% inhibition) of the activity
to decrease the pathway flux to the levels reached by inhibiting a
flux-controlling step. However, there are experimental evidences
indicating that oxamate and iodoacetate, presumed specific
inhibitors of LDH and GAPDH, i.e., two non-controlling
glycolytic enzymes, do affect the glycolytic flux of cancer,
and non-cancer cells (Goldberg et al., 1965; Elwood, 1968;
McKee et al., 1968; Coe and Strunk, 1970; Chatham et al.,
1988; Moreno-Sánchez et al., 2016). Remarkably, this inhibition
induces accumulation of Fru1,6BP and DHAP, being the former
an inhibitor of HK (controlling enzyme), TPI, and GAPDH,
whereas the latter is an inhibitor of HPI (another controlling
enzyme; published data summarized in Supplementary Table 2).
The effect of oxamate on the activities of LDH, GAPDH,
ENO, and PYK, which in turn affected the Fru1,6BP and DHAP
concentrations (Moreno-Sánchez et al., 2016), was here in silico
examined focusing on the concentration control coefficients for
Fru1,6BP and DHAP by using the updated and modified kinetic
models of AS-30D and HeLa glycolysis. These models were
further refined (described in Section Kinetic Modeling) with
respect to the models previously published (Marín-Hernández
et al., 2014; Moreno-Sánchez et al., 2016). Enzymes that produce
a metabolite have positive concentration control coefficients
whereas those that consume it have negative ones (Fell, 1997).
For glycolysis of AS-30D hepatocarcinoma cells, the model
simulations indicated that GLUT, HK, and HPI have high
positive concentration control coefficients values (from 1 to 2.3),
whereas ENO (−0.57 and −0.99), PYK (−0.4 and −0.7), and
GAPDH (−0.16 and −0.27) have high negative concentration
control coefficients values on Fru1,6BP and DHAP, respectively
(Table 1). For HeLa cells cultured for 24 h under different glucose
concentrations (normo-, hypo-, or hyper-glucemic conditons)
kinetic model simulations showed that GLUT, HK, and HPI
also exert control on the synthesis of the same two metabolites,
whereas GAPDH (−0.7 and −1.3) and PYK (−1.3 and −3)
control their consumption (Table 1). Hence, in both types of
cancer cells, the enzymes with high positive concentration
control coefficients on Fru1,6BP and DHAP were those that
also exerted the main control on the glycolytic flux (GLUT, HK,
and HPI) and hence, their inhibition should decrease Fru1,6BP
and DHAP concentrations. In contrast inhibition of GAPDH,
ENO, and PYK, which have high negative concentration control
coefficients should increase the levels of Fru1,6BP and DHAP.
It is worth noting that without kinetic modeling it would not
have been possible to unveiled the important role of GAPDH,
ENO, and PYK on the indirect modulation of the flux-controlling
enzymes by Fru1,6BP andDHAP. By the present in silico analysis,
these other metabolic regulatory mechanisms of cancer glycolysis
became apparent and were further analyzed.
In the AS-30D kinetic model it was evaluated the effect of
LDH, ENO or PYK inhibition on the levels of Fru1,6BP and
DHAP. LDH showed low control on their concentrations (−0.4
and −0.02; Table 1) since an 80% decrease in its activity only
induced a marginal increase in their concentrations (Figure 1);
identical results were attained with PGK and PGAM (data
not shown). In contrast, a similar inhibition of ENO and
PYK activities led to marked accumulation of Fru1,6BP and
DHAP (Figures 1A,C). Similar results were obtained with the
HeLa model under hypoglycemia when modulation of the
GAPDH, PYK, PGK, PGAM, and LDH activities were simulated
(Figures 1B,D). These analyses strongly suggested that the
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TABLE 1 | Concentration control coefficients of glycolytic steps on Fru1,6BP, and DHAP obtained in silico using the updated kinetic models of glycolysis
in AS-30D and HeLa cells (see Section Materials and Methods) under normoxia (20% O2).
Enzymes AS-30D cells HeLa cells
Hyperglycemia Normoglycemia Hypoglycemia
Fru1,6BP DHAP Fru1,6BP DHAP Fru1,6BP DHAP Fru1,6BP DHAP
GLUT 1.9 1 0.66 0.36 0.72 0.4 2.5 1.5
HK 2.3 1.3 2.3 1.3 2.4 1.4 1.9 1.1
HPI 1.9 1.1 1.5 0.8 1.3 0.7 0.8 0.4
PFK1 0.2 0.1 0.7 0.4 0.9 0.5 0.7 0.4
ALDO −0.4 −0.003 −0.3 0.0007 −0.4 −0.0007 −0.6 0.001
TPI −0.06 −0.06 −0.004 −0.004 −0.004 −0.004 −0.008 −0.008
GAPDH −0.27 −0.16 −1.3 −0.7 −1.2 −0.7 −1.2 −0.7
PGK −0.1 −0.08 −0.01 −0.008 −0.02 0.01 −0.02 −0.01
PGAM −0.09 −0.05 −0.05 −0.03 −0.06 −0.03 −0.07 −0.04
ENO −0.99 −0.57 −0.06 −0.03 −0.06 −0.03 −0.07 −0.05
PYK −0.7 −0.4 −3 −1.7 −2.5 −1.5 −2.0 −1.3
LDH −0.04 −0.02 −0.03 −0.02 −0.02 −0.01 −0.03 −0.02
MCT −0.2 −0.1 −0.2 −0.1 −0.1 −0.07
FIGURE 1 | Dependence of Fru1,6BP and DHAP concentrations on the
activity of different pathway enzymes of cancer glycolysis. The
reference 100% enzyme activity values were those corresponding to the
respective Vmax values for the forward reaction whereas Fru1,6BP and DHAP
concentrations were those predicted by each model (A,C for AS-30D cells;
B,D for hypoglycemic HeLa cells). When two enzymes were simultaneously
titrated, identical variation in the activities was applied. In the case of LDH,
ENO, and GAPDH, a decrease of the Vmaxf value was accompanied by a
proportional decrease in the Vmaxr value.
increase in Fru1,6BP and DHAP levels reported in AS-30D,
Ehrlich ascites, sarcoma 37 ascites and HeLa cells treated with
oxamate (Goldberg et al., 1965; Elwood, 1968; Coe and Strunk,
1970; Moreno-Sánchez et al., 2016), was a consequence of ENO
and PYK inhibition rather than of LDH inhibition, contrary to
the most common interpretation.
To further establish the influence in the glycolytic flux
and ATP concentration of the inhibitory effect of Fru1,6BP
and DHAP on flux-controlling (HK and HPI) and not
flux-controlling (TPI and GADPH) enzymes, several simulations
were made with the AS-30D model (Figure 2). When inhibition
of Fru1,6BP and DHAP was not included in the rate equations
of HK, HPI, TPI and GAPDH, the decrease of ENO and PYK
activities still increased the levels of Fru1,6BP and DHAP but
the concentration of ATP and glycolytic flux were not modified
(Figure 2). A similar effect was observed when inhibition
of Fru1,6BP on the TPI and GAPDH rate equations was
included (data not shown). These last observations indicated that
inhibition of ENO and PYK activities per-se was not sufficient
to decrease the glycolytic flux. Only when the Fru1,6BP and
DHAP inhibitions on the HPI and HK rate equations were
included, the glycolytic flux and ATP concentration decreased
(Figure 2).
Furthermore, the Fru1,6BP andDHAP levels indeed increased
in cells treated with oxamate (reported by Moreno-Sánchez et al.,
2016) or iodoacetate (Table 2). These experimentally determined
metabolite concentrations were also closely simulated by kinetic
modeling when decreasing by ∼75% the ENO+PYK activities,
and including the Fru1,6BP and DHAP inhibition of HK, or
HPI, or both HK+HPI, or HPI+HK+TPI+GAPDH (Figure 2).
Hence, the interactions of these metabolites with HK and HPI
are apparently also involved in themechanisms of control of their
own intracellular levels. Incubation with oxamate or iodoacetate
promoted a severe decrease (3.5–4.6 times vs. control) in the
intracellular ATP (Table 2). Although cell viability remains high
(>90%), it may be possible that these inhibitors also affect
the mitochondrial function thus perturbing the cell ATP levels
(Martin-Requero et al., 1986; Cano-Ramírez et al., 2012). Since a
significant HK fraction in cancer cells is bound to mitochondria,
OxPhos also provides ATP for this glycolytic reaction. However,
this interplay between glycolysis and OxPhos through the
ATP/ADP ratio has not been included in the present kinetic
models because the subcellular distribution of the HK isoforms
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FIGURE 2 | Effect of ENO and PYK inhibition on Fru1,6BP, DHAP, and
ATP concentrations and glycolytic flux. The kinetic model for AS-30D
glycolysis was used. ENO plus PYK activities were modulated and the effects
on Fru1,6BP (A), DHAP (B), glycolytic flux (C), and ATP (D) were determined.
Several simulations were made with or without enzyme inhibition by Fru1,6BP
and DHAP on no enzyme (a); on HPI (b); on HK (c); on both HPI and HK (d);
and on HPI, HK, TPI, and GAPDH (e). The respective HPI, HK, TPI, and
GAPDH rate equations with Fru1,6BP and DHAP inhibition are depicted in the
Methods Section.
has not been determined under the different O2 and glucose
culture conditions.
Accumulation of Toxic Metabolites
Contributes to Decrease Cancer Glycolysis
Another possible consequence of DHAP accumulation is
the production of methylglyoxal, which can also inhibit the
glycolytic flux in cancer and normal cells (Leoncini et al., 1989;
Halder et al., 1993; Biswas et al., 1997). In this regard, cells
treated with oxamate showed increased methylglyoxal levels
(Table 2). Similarly, significant increases in Fru1,6BP, DHAP and
methylglyoxal were observed in cells treated with iodoacetate
(Table 2). This last inhibitor primarily affects GAPDH (Sabri and
Ochs, 1971), which also exerts control on the concentrations of
Fru1,6BP and DHAP (Table 1). In addition, in the iodoacetate-
treated cells, significant decreases in the ATP concentrations
and glycolytic flux were observed with respect to control cells,
whereas the Glc6P and Fru6P levels did not change (Table 2). All
these changes in metabolites and glycolytic flux were similar to
those previously observed in cells treated with oxamate (Table 2;
and Moreno-Sánchez et al., 2016). Therefore, it is suggested
that iodoacetate induces glycolysis inhibition mainly through
accumulation of Fru1,6BP and DHAP.
Methylglyoxal affects PYK and GAPDH activities (Leoncini
et al., 1989; Halder et al., 1993; Biswas et al., 1997). However,
in cells treated with iodoacetate (2mM) or oxamate (20mM)
no changes were attained in these enzyme activities (data
not shown). This discrepancy may be attributed to the high
concentrations of methylglyoxal (2.5mM) used in previous
papers (Leoncini et al., 1989; Halder et al., 1993). Alternatively,
the glyoxalase system in AS-30D cells might be highly efficient
TABLE 2 | Fru1,6BP and DHAP concentrations in AS-30D cells treated with
oxamate or iodoacetate.
Metabolite/
flux
Control Iodoacetate (mM) Oxamate (mM)
2 4 10 20
Glc6P 10 ± 5 (3) 3.9 ± 2 (4) 3.5 ± 2 (3) 4a 4a
Fru6P 2 ± 1 (3) 1.5 ± 0.3 (3) 1.6 ± 0.5 (3) 1.2a 1.3a
Fru1,6BP 2.4 ± 1.7 (3) 7 ± 1 (3)* 8 (2)c 23a 22a
DHAP 1.8 ± 0.4 (5) 33 ± 9 (3)** 17 (2)c 11a 11a
ATP 6 ± 2 (3) 1.4 ± 0.5 (3)* 1.3 ± 0.3 (3)* 1.7a 1.4a
Glycolytic
flux
8 ± 3 (3) 2 ± 2 (4)* 1 (2)c 4.3a 4.2a
Methylglyoxalb < 0.3 (4)d 2.2 ± 0.6 (3) N.M. N.M. 3.6 ± 1.6 (4)
Cells were incubated in Krebs-Ringer medium with no glucose added at 37◦C for 1 h with
the indicated inhibitor concentrations. Then, 5mM glucose was added and the metabolite
concentrations and glycolytic flux were determined after 10min. Metabolites in mM. Fluxes
in nmol/min*mg protein.
aFor comparison, these values were taken from Moreno-Sánchez et al. (2016).
bMethylglyoxal in nmol/mg protein.
cThe independent experiment values showed a 15% difference between them.
dThe limit of methylglyoxal detection was ∼0.3 nmoles.
Asterisks indicate statistically significant differences compared with control (*P ≤ 0.05,
**P ≤ 0.0005) using Student’s t-test for non-paired samples. The data shown represent
the mean ± standard deviation with the number of independent preparations assayed
between parentheses. N.M. not measured.
for methylglyoxal detoxification, a hypothesis that remains to be
experimentally determined.
Effect of the Inhibition Mechanism of HPI
on Pathway Properties
In the previous sections it was shown that it is indeed
possible to significantly inhibit glycolysis by affecting non-flux
controlling enzymes. Traditionally, competitive inhibitors have
been studied or designed for drug therapy. However, such type
of inhibitors induces substrate accumulation which in turn
eventually displaces the inhibitor from the enzyme binding site,
attenuating its inhibitory impact. Therefore, it was interesting to
test with the present kinetic model the effect of different types
of inhibition mechanisms on the pathway flux. This is relevant
because the experimental results above showed accumulation
of metabolites that affect the activities of the main controlling
enzymes. Therefore, the kinetics of a flux-controlling step such
as HPI was analyzed. This enzyme catalyzes a monosubstrate
reaction and is strongly regulated by Fru1,6BP, Ery4P, and
6PG (Supplementary Table 2) which are competitive inhibitors
(Marín-Hernández et al., 2011). In these simulations, DHAP
was not included as HPI inhibitor because it only affects at
high concentrations (KiDHAP = 9.4mM and in HeLa cells
physiological concentrations of DHAP are 0.5–0.8mM; Marín-
Hernández et al., 2014).
The first versions of the kinetic model of cancer glycolysis
previously published predicted low levels of Glc6P and high
glycolytic flux which were in disagreement with the experimental
values. The model refinement process indicated that HPI activity
should be inhibited to properly simulate the experimental values
(Marín-Hernández et al., 2011). Thus, it was experimentally
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determined that physiological levels of Ery4P, 6PG, and Fru1,6BP
competitively inhibited HPI activity vs. Fru6P or Glc6P
(Marín-Hernández et al., 2011; Moreno-Sánchez et al., 2016;
published data summarize in Supplementary Table 2). Then,
multiple competitive-type inhibition was incorporated in the
HPI rate-equation to accurately simulate the experimental Glc6P
concentrations and glycolytic flux (Marín-Hernández et al.,
2011). Here it was now explored the effect that different types
of HPI inhibition have on pathway metabolite concentrations
and flux to establish which kind of inhibitor is more efficient in
blocking controlling steps and glycolytic flux.
For competitive inhibition, the effect of changing the affinities
(1/Ki) of HPI inhibitors was modeled. A decrease of 90% in theKi
value (i.e., the affinity values for inhibitors were increased by 10-
fold) increased the HPI flux-control coefficient to a value of 0.27
(Figure 3A). The reason for this behavior was that accumulation
of Glc6P (Figure 3C) attenuated the binding of the physiological
inhibitors to HPI and also exerted strong inhibition on HK.
Furthermore, the HPI flux control remained unchanged (0.25)
when the Ki value was decreased 100-fold (Ki= 0.01; Figure 3A),
but the glycolytic flux drastically decreased as a consequence of
HK inhibition by accumulated Glc6P.
When HPI inhibitors were all considered as uncompetitive
or mixed type inhibitors in the kinetic model of hypoglycemic
HeLa cells, it was necessary to decrease their affinities by 6–
10 times (i.e., their Ki values were increased 6–10) to keep
unaltered the HPI flux-control coefficient, pathway flux and
Glc6P concentration (Figures 3A–C, respectively). However, it
was noted that with uncompetitive inhibition, an increase in the
Ki values by only three-fold yielded a high flux control coefficient
of 0.65 with concomitant remarkable suppression of pathway
flux and accumulation of Glc6P. This enhanced accumulation of
substrates of the inhibited enzyme by uncompetitive inhibitors
(vs. competitive inhibitors) was envisioned three decades ago
(Cornish-Bowden, 1986), but perhaps because examples of
uncompetitive inhibition have not been profusely found, studies
on this issue have not been developed. With mixed-type
inhibition, the three-fold increase in Ki values brought about
milder effects on HPI flux control, pathway flux and Glc6P
concentration.
These in silico simulations suggested that both uncompetitive
and mixed-type inhibition can perturb the pathway flux, at a
significantly greater extent than competitive inhibition, because
these types of inhibition affect Vmax (which is not altered by
competitive inhibitors) and catalytic efficiency (Vmax/Km). It
is recall that the Vmax value is directly linked to the content
of active enzyme (Vmax = kcat × [enzyme]total) and hence to
transcriptional/translational regulation and protein degradation.
The design of new inhibitors should consider the uncompetitive
and mixed-type inhibition mechanisms to generate potent drugs
against cancer glycolysis.
Docking Analysis Predicts Potency of
Regulatory Metabolites of HPI
To explore why regulatory metabolites may have different
potencies, a docking analysis of metabolic inhibitors was
FIGURE 3 | Effect of changing the Ki value and inhibition mechanism of
tumor HPI on (A) HPI flux control coefficient; CJ
HPI
, (B) pathway flux
and (C) Glc6P concentration. Using the kinetic model for hypoglycemic
HeLa cells, increasing Ki values for Ery4P, Fru1,6BP, and 6PG were simulated
with competitive, uncompetitive or mixed type inhibition mechanisms. In the
case of mixed type inhibition, α = 2. The dashed line indicates the normalized
Ki value which was experimentally determined (KiEry4P = 1µM; KiFru1,6BP =
60µM; Ki6PG = 15µM).
performed on HPI. This analysis showed that the HPI
competitive inhibitors can indeed adequately bind to the
substrate binding site and be stabilized by the same amino acids
in the active site (Figure 4). The binding energies were −5.62
(Ery4P), −4.57 (6PG), −3.63 (Fru1,6BP), and −2.64 (DHAP)
Kcal/mol. The estimated Ki values (in mM) were 0.076 (Ery4P),
0.45 (6PG), 2.2 (Fru1,6BP), and 11.6 (DHAP) which indicated
that Ery4P and 6PG bind more tightly to the enzyme active
site compared with the other two metabolites. These results
correlated with previous data indicating that the most potent
HPI inhibitors are Ery4P (Ki = 0.8–2.5µM) and 6PG (Ki =
6.8–18µM; Marín-Hernández et al., 2011). The discrepancy
between the theoretical and experimental Ki values may be due
to limitations in the docking procedure since for the analysis,
the enzyme structures were considered rigid whereas only the
ligands were flexible (for the limitation in the number of rotating
bonds that can be assigned). However, enzyme structures are
flexible and upon substrate or modifier binding, the active sites
Frontiers in Physiology | www.frontiersin.org 9 September 2016 | Volume 7 | Article 412
Marín-Hernández et al. Non-controlling Steps Inhibition Decreases Cancer Glycolysis
FIGURE 4 | Docking of metabolic inhibitors into mouse hexose phosphate isomerase active site. (A) Structure of the dimer of mouse HPI showing the
substrate Glc6P (red spheres) bound to one of the active sites. The active site of each monomer is formed by a cleft between two domains at the dimer interface.
(B) Backbone representation of the residues located within 4 Å of the ligands (shown as sticks) bound in the active site. Residues colored cyan belong to subunit B of
the dimer.
have in general conformational changes that in most cases favor
tighter ligand coupling. However, despite these limitations, the
docking data analysis predicted the order of binding efficiency
and potency of the HPI inhibitors. Also, docking analysis showed
that Fru1,6BP can bind to the active sites of HK, TPI, and
GAPDH (Supplementary Figure 1).
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DISCUSSION
Feedback Inhibition by Glycolytic
Intermediaries on Flux Controlling
Enzymes
A recent study by our group (Moreno-Sánchez et al., 2016)
showed that oxamate inhibition of cancer glycolysis was
mediated by the direct moderate inhibition of several pathway
sites such as LDH, PYK, and ENO. The simultaneous oxamate
inhibition of these non-controlling enzymes induced the
accumulation of Fru1,6BP and DHAP, which behaved as
inhibitors of HK, HPI, TPI, and GAPDH. In the present
study, it was shown that inhibition of down-stream non-
controlling enzymes may affect pathway flux only if Fru1,6BP
and DHAP are accumulated. It was also shown that the
mechanistic basis of this glycolysis suppression was to
specifically block the steps with predominant control on
the Fru1,6BP and DHAP concentrations, which were PYK,
ENO, and GAPDH, but not LDH or PGK. Perturbation
of other pathways by inhibiting non-controlling steps may
occur as long as the ensuing accumulation of metabolites
affects the activities of the main controlling steps. For
instance, inhibition of malate dehydrogenase, a Krebs cycle
non-controlling step, brings about accumulation of NAD+,
malate, fumarate, and succinate. And high levels of these
metabolites may alter the activities of isocitrate and 2-
oxoglutarate dehydrogenases, the main controlling steps of
Krebs cycle.
Although iodoacetate is an unspecific drug that may
covalently alkylates thiol groups at the active sites of many
enzymes and hence may show toxicity, treatment of Ehrlich
ascites carcinoma-bearing mice with iodoacetate significantly
increases the median cumulative survival time and percentage
of survivors, as well as decreases the tumor size (Fahim
et al., 2003). Similarly, oxamate is able to inhibit the
chondrosarcoma and nasopharyngeal carcinoma growth in
nude mice (Li et al., 2013; Hua et al., 2014). It should
be noted that the observed improvement in tumor-bearing
animals treated with these compounds is the result of several
combined processes including abolishment of tumor glycolysis
and activation of several rescue pathways such as immune system
(Rheins et al., 1975) and antioxidant defense (Fahim et al.,
2003).
Although the drugs tested (oxamate and iodoacetate) might
have similar effects on non-cancer cells, both inhibitors are well-
tolerated in animals and human non-cancer cell lines, suggesting
that normal cells are less sensitive to glycolysis inhibition, likely
due to a lower dependence on glycolysis for their proliferation
with respect to tumor cells. In addition, glycolysis inhibition
of tumor associated fibroblasts (reverse Warburg effect) may
be also beneficial to deter tumor growth (Pavlides et al., 2009;
Martinez-Outschoorn et al., 2011).
As suggested by the data of the present study, the anticancer
effect observed of these unspecific drugs (Fahim et al., 2003; Li
et al., 2013; Hua et al., 2014)may be associated with the inhibition
of glycolysis mediated by (i) the accumulation of Fru1,6BP
and DHAP which in turn inhibit the main flux-controlling
FIGURE 5 | Glycolysis inhibition by accumulation of
fructose-1,6-bisphosphate and dihydroxyacetone phosphate. Inhibition
of ENO and PYK by oxamate, GAPDH inhibition by iodoacetate, induces
accumulation of Fru1,6BP and DHAP, which behave as inhibitors of HK, HPI,
GAPDH, and TPI at high concentrations, leading to a decrease in the L-lactate
production (glycolysis inhibition). High levels of DHAP produce methylglyoxal
that is converted in D-lactate by the glyoxalase system. PPP, pentose
phosphate pathway.
enzymes HK and HPI (Figure 5); and (ii) the accumulation of
methyglyoxal. For cancer treatment, this mechanism may help
in the design of new strategies to inhibit essential metabolic
pathways such as OxPhos, the antioxidant system and anabolic
routes.
Based on the in silico kinetic modeling analysis indicating
that both uncompetitive and mixed-type inhibitors can perturb
at a significantly greater extent the pathway flux and metabolite
concentrations than competitive inhibitors, it is concluded
that elevation of the Fru1,6BP levels will have a more severe
depressing effect on the glycolytic flux of cancer cells than that
of DHAP levels because the former behaves as a mixed-type
inhibitor of HK whereas the latter competitively inhibits HPI
(Moreno-Sánchez et al., 2016).
Synthesis of Toxic Metabolites for Cancer
Glycolysis
Fru1,6BP is a product of the PFK-1 reaction and a weak
inhibitor of HK, HPI, GAPDH, and TPI (Marín-Hernández
et al., 2011; Moreno-Sánchez et al., 2016). In addition of
being an activator of PYKM2, Fru1,6BP may indirectly inhibit
oxidative phosphorylation (Mazurek et al., 2002; Díaz-Ruiz
et al., 2008). On the other hand, DHAP is one of the two
products of Fru1,6BP breakdown, it is a weak HPI inhibitor
(Moreno-Sánchez et al., 2016) and together with glyceraldehyde-
3- phosphate represent the most important endogenous source
of methylglyoxal (Allaman et al., 2015). The latter compound
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is one of the most potent glycating agents naturally produced
within cells; it reacts with proteins, lipids and nucleic acids to
form advanced glycation end products (AGEs; Allaman et al.,
2015). High levels of this metabolite can be reached when
the concentrations of their precursors are elevated, such as in
impaired glucose utilization and TPI deficiency (Ahmed et al.,
2003). The glyoxylase system is the main ubiquitous pathway
for methylglyoxal detoxification (Figure 5) and is involved
in tumor development, growth, migration, apoptotic evasion,
and multidrug resistance. Increased levels and activities of
glyoxylases 1 and 2 in diverse types of cancer (bladder, breast,
colon, lung, and prostate) have been observed (Thornalley and
Rabbani, 2011; Geng et al., 2014). Therefore, they have been
considered as malignancy biomarker and potential anti-cancer
target.
One attractive novel approach for targeting cancer cells,
derived from the present study, which deserves further
experimental assessment, is the use of inhibitors of GAPDH,
ENO, and PYK together with glyoxylase inhibitors, which
at relatively low doses do not perturb host homeostasis.
This particular multi-drug treatment would induce DHAP
accumulation which in turn would lead to enhanced levels of
methylglyoxal, severely compromising cancer cell growth and
viability. Although, methylglyoxal has several toxic effects, it has
shown anticancer activity in tumor-bearing mice and slight side-
effects (Ghosh et al., 2006). Furthermore, high concentrations
of methylglyoxal (2–7.5mM) strongly inhibits OxPhos and
glycolysis, drastically decreasing the ATP level in cancer cells and
apparently showing no effect on normal cells and tissues (Ray
et al., 1991; Biswas et al., 1997). In tumor-bearing animals similar
high levels of methylglyoxal concentrations in blood (13–19mM)
had no apparent toxic effect on vital organs (liver, kidney) but
increased their life span by inhibiting tumor growth (Ghosh
et al., 2006). This therapeutically exciting difference has been
attributed to alterations in complex I and GAPDH of tumor
cells that increase sensitive to methylglyoxal with respect to non-
tumor enzymes (Biswas et al., 1997; Ray et al., 1997). Other
reports indicate that methylglyoxal (30µM) inhibits complex III
and ATP synthesis in vascular smooth A-10 cells (Wang et al.,
2009).
Uncompetitive Inhibition Is the Most
Potent Mechanism to Block Glycolytic Flux
There are three mechanisms by which a reversible inhibitor may
interact with an enzyme: competitive, uncompetitive, and mixed
type inhibition (Segel, 1975); the non-competitive inhibition
should be considered as a special, non-common case of mixed-
type inhibition. A molecule that is structurally similar to the
natural substrate may reversible bind to the enzyme active site
and act as a competitive inhibitor. In this regard, docking
simulations were performed to support this assumption for
HPI since the regulatory metabolites Fru1,6BP, Ery4P, 6PG,
and DHAP readily bind to the substrate binding site and are
stabilized by the same amino acids involved in the Glc6P
and Fru6P binding (Figure 4). Thus, competitive inhibitors
are common in metabolic pathways because the products of
each reaction and several other pathway intermediaries have
structural similarity with the substrate. As a consequence,
Fru1,6BP, Ery4P, and 6PG behave as competitive inhibitors of
HPI vs. the substrate Glc6P and product Fru6P, regulating the
supply of Glc6P for pentose phosphate and glycogen synthesis
pathways.
Nevertheless, competitive inhibitors can be also readily
displaced from the active site by high substrate concentrations,
thereby restoring enzyme activity. Thus, the physiological effect
of competitive inhibitors is to provide an immediate response of
the targeted enzyme/transporter which will be attenuated in the
medium term. Then, although competitive inhibitors are easier
to find in nature or be designed and manufactured, they are not
pharmacologically efficient drugs.
In contrast, the effects of the uncompetitive and mixed-type
inhibitors cannot be overcome by increasing the substrate
concentration; in fact, for uncompetitive inhibition it becomes
more significant at increasing substrate concentrations
(Cornish-Bowden, 1986). Using a kinetic model of the
parasite Trypanosoma brucei glycolysis it was concluded
that inhibition of the pyruvate transport would be more
effective for perturbing the pathway with an uncompetitive
inhibitor (followed by mixed-type) than with a competitive
one (Eisenthal and Cornish-Bowden, 1998). Although,
uncompetitive inhibitors are not common, there are
recent reports about the identification of uncompetitive
inhibitors of human γ-glutamyl transpeptidase and P-
glycoprotein, proteins that can play an important role in
drug-resistance in cancer (Wickham et al., 2013; Teng et al.,
2015).
Uncompetitive and mixed-type inhibitions modify the Vmax
value, which is a kinetic parameter that has a strong influence on
the degree of control that each pathway enzyme exerts (Marín-
Hernández et al., 2014). GLUT was the main controlling step of
glycolysis in HeLa hypoglycemic cells and T. brucei because its
activity (i.e., Vmax) was the lowest (Bakker et al., 1999; Marín-
Hernández et al., 2014). In contrast, PFK-I has low activity in
tumor cells but it has no control on the pathway flux because
Fru2,6BP activation increases several-fold its activity (Moreno-
Sánchez et al., 2012).
CONCLUSION
Kinetic modeling studies have shown that only the simultaneous
inhibition of several flux-controlling steps will have significant
impact on glycolytic flux and ATP concentration in cancer
cells. This can be accomplished by direct inhibition using,
preferentially, uncompetitive specific drugs or indirectly
through the accumulation of regulatory metabolites of the
flux-controlling steps by inhibiting enzymes that exert low
flux-control.
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